Bristol-Myers Squibb Stock News

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. The company will take part in a fireside chat beginning at 8:30 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An arch...

I use YCharts' Value Score and Ben Graham Formula to identify large-cap value stocks offering strong intrinsic value and stable dividends. Analyst forecasts suggest top-ten GASV 'Dogs' could deliver 17.9% to 36.88% net gains by August 2026, with average gains near 23.6%. Eight of fourteen 'safer' lowest-priced GASV stocks are currently fair-priced and buyable, combining positive free cash flow ...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025.

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream and offer a promising avenue for total return.

First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J.

Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Analyst forecasts suggest the top ten S&P 500 dividend dogs could deliver 23% to 40% net gains by August 2026, with moderate risk. A market correction or dividend increases could make all top ten 'safer' dividend dogs attractively priced, maximizing yie...

The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year, driven by strong corporate earnings, AI productivity, and a likely lower rate environment. Recent additions to the portfolio—BMY, SLB, and AGNC—reflect my focus on undervalued, high-yield opportun...